Browse more cannabis research, findings, methods, and limitations.
US children's hospital data showed substance-related visits grew 48% from 2016-2021, with cannabis dominating (52% of visits, 82% growth) and Hispanic youth seeing the largest increase.
Survey of 5,433 Canadians found medical cannabis authorization associated with fewer side effects, better dosing knowledge, more regulated sources, and more professional guidance.
Arkansas data showed cancer patients with medical marijuana cards had 24% lower odds of antiemetic overuse during chemotherapy, suggesting cannabis may support more appropriate prescribing.
Veterans who quit smoking had 75% higher odds of reducing cannabis use and 2x higher odds of reducing alcohol use, but quitting did not improve depression, anxiety, or pain.
Smoked marijuana causes bronchitis symptoms and airway changes, but hasn't been linked to progressive lung function decline or clearly increased lung cancer risk — a paradox given its similarity to tobacco smoke.
Computational analysis mapped how 8 phytocannabinoids interact with neurodegenerative disease targets through ErbB and PI3K-Akt pathways, with effects varying by sex, age, and disease.
Review of 24 studies found youth cannabis use linked to depression, psychosis, suicide, and cognitive decline in Australia and the US, with effects worsening with heavier use.
Survey found 41% of cancer patients used cannabis during active treatment, with depression and pain as top reasons, and 13% unsure what cannabinoid they were consuming.
ABCD Study of 9,000+ adolescents linked prenatal cannabis exposure to frontal/parietal brain differences, with some changes partially explaining the pathway to ADHD.
Registry study of 70 Tourette's patients found medical cannabis improved quality of life and sleep but did not significantly reduce tics, with mild side effects.
Analysis found Uruguay's cannabis legalization was driven by political strategy and public security concerns, with tobacco/alcohol comparisons used to justify the market rather than reflecting genuine health policy coordination.
Two cannabis extracts matched gabapentin for neuropathic pain relief in rats, with complex effects on brain cannabinoid receptors that varied by region and dose.
California CUD treatment admissions declined after legalization, particularly for White males, while increasing for criminal justice referrals and Black and Hispanic patients.
Meta-analysis of 534,445 participants found prenatal cannabis slightly increased ADHD risk (13%) and offspring cannabis use (20%) but showed no link to autism, psychosis, anxiety, or depression.
Study of 80 adolescents found half used synthetic marijuana alongside natural, primarily to save money and avoid drug tests, with dual users showing more behavioral problems.
Qualitative study found 14 adults in early opioid/stimulant recovery used cannabis to manage cravings, withdrawal, and psychiatric symptoms while experiencing typical recovery benefits.
Pilot mobile app helped heavy cannabis users cut use from 94% of days to 47% and from 1.42 grams to 0.61 grams daily, with half achieving 50%+ reduction.
Review found FDA-approved CBD causes dose-dependent liver toxicity, with higher risk when combined with valproate, and current models cannot fully predict CBD safety.
Pennsylvania health system found medical marijuana documentation captured conditions and products well (93%) but dosage poorly (31%), highlighting gaps in clinical cannabis tracking.
Ontario data showed cannabis was the most common substance (52.8%) in suspected impaired drivers from 2008-2019, with 80% of cases involving multiple drugs.
Adding Finger-to-Nose test and head movement observations to the standard sobriety test improved cannabis impairment detection from 67% to 88% sensitivity.
Evidence-based guidelines found moderate support for cannabinoids in chronic pain, with benefits for sleep, anxiety, and conditions like MS and fibromyalgia. Emphasize patient education and collaborative dosing.
National database of 344,000 bypass patients found marijuana users had 40-64% higher odds of kidney injury, heart attack, and stroke after surgery despite being younger.
Study found youth with more sleep trouble used more cannabis overall, but on specific bad-sleep nights, they were actually less likely to use the next day.
Survey of 498 caregivers found CBD improved seizures in 85% of severe epilepsy patients, plus alertness, cognition, and emotional functioning even in some without seizure improvement.
Audit of 150 cannabis retailers across 5 US cities found less regulatory signage in minority communities and varying marketing practices by neighborhood demographics.
A CB2 cannabinoid receptor genetic variant was associated with 61% lower odds of priapism in sickle cell anemia patients — connecting the endocannabinoid system to blood vessel complications.
Review warns that prenatal cannabis use is rising despite evidence of perinatal and neurodevelopmental risks, with healthcare providers often avoiding the topic.
Large survey found 20% of pregnant women used CBD-only products, nearly double the rate of non-pregnant women, primarily for anxiety, pain, and depression.
Two-thirds of Colorado mothers reported clinician cannabis discussions during pregnancy, but perinatal users more often trusted cannabis websites and stores for information.
Four-week study found CBD-dominant cannabis reduced anxiety, tension, and paranoia more than THC-dominant cannabis in people with anxiety symptoms, with THC not worsening anxiety.
Frequent cannabis users reported difficulty filtering sensory stimuli and heightened emotional body awareness compared to non-users, with effects increasing with more use days.
Survey of 505 medical patients found recreational legalization reduced stigma and legal stress but increased prices, with mixed effects on product accessibility.
Analysis found US medical cannabis registries focus on patient counts and sales data while largely failing to track safety outcomes, demographics, or therapeutic benefits.
National survey found Americans mostly get cannabis information from friends (36%) and websites (34%), with only 9% consulting healthcare providers and 5% using government sources.
Survey of 763 rheumatic disease patients found 63% substituted medical cannabis for other medications, most commonly NSAIDs and opioids, reporting fewer side effects.
US medical cannabis grew to 4.1 million patients by 2022 but declined in recreational states, with increasing use for conditions without strong evidence support.
Study found moderate agreement (kappa=0.49) between self-report and urine tests for prenatal cannabis use, with discordance explained by low-level use and pre-awareness consumption.
Review of 70 studies found attitudes toward cannabis-impaired driving are mostly negative but mixed, with youth and frequent users more favorable and perceived enforcement risk low.
Review found cannabis causes several adverse eye effects including impaired night vision and corneal changes, while debunking its use for glaucoma and identifying potential treatments for blepharospasm and dry eye.
First GRADE-based emergency department guidelines for CHS recommend haloperidol/droperidol and topical capsaicin alongside standard antiemetics, though evidence certainty remains very low.
In C. elegans worm models, CBD and THC both reduced pain responses but through entirely different receptor systems, with CBD effects wearing off within 6 hours while THC effects persisted.
Analysis of 10 million insured patients found cannabis laws were associated with 12-15% fewer benzodiazepine fills but increases in antidepressant and antipsychotic prescriptions, suggesting complex effects on mental health treatment patterns.
COVID-19 patients showed significantly higher endocannabinoid concentrations in extracellular vesicles than in plasma, with levels increasing alongside disease severity, suggesting EVs serve as an endocannabinoid delivery system during infection.
First ASCO guideline on cannabis in cancer advises against using it as a cancer treatment outside trials, but notes it may help with chemotherapy nausea that does not respond to standard antiemetics.
Mouse study found neither THC nor synthetic cannabinoid JWH-073 killed heart cells, but JWH-073 caused significantly greater blood vessel relaxation, offering a potential mechanism for cardiovascular events seen with K2/Spice products.
Female rats showed cannabinoid withdrawal at lower antagonist doses than males, and the specific withdrawal behaviors differed by sex, supporting clinical observations that cannabis withdrawal manifests differently in women.
Across 14 European sites, lower homeownership and higher daily cannabis use prevalence each independently predicted psychosis incidence, with daily cannabis use specifically linked to affective psychosis.
Among 311 adults with HIV, current cannabis use disorder was linked to higher apathy scores, but the association disappeared after accounting for depression, suggesting the relationship may be driven by overlapping symptoms.
Occasional cannabis users showed impaired reaction time and memory after smoking, while daily users showed tolerance to these effects but still took longer on a driving-related decision task without losing accuracy.